Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs MiniMed Group Inc. Common Stock (MMED) Price & Performance

Ginkgo Bioworks Holdings IncTrade
MiniMed Group Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs MiniMed Group Inc. Common Stock — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.09 (market cap $763.64M), while MiniMed Group Inc. Common Stock trades at $19.57 (market cap $5.57B). The key difference: MiniMed Group Inc. Common Stock is far larger — about 7.3× Ginkgo Bioworks Holdings Inc's market cap, and MiniMed Group Inc. Common Stock is more actively traded (23,336,073 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and MiniMed Group Inc. Common Stock for 0 Days on average.

DNAMMED
Market Cap
$763.64M$5.57B
Volume
3,204,17723,336,073
Sector
HealthHealth
52-Week High
$15.83$23.84
52-Week Low
$5.48$10.80
Typical Hold Time
7 Days0 Days
Enterprise Value
$865.59M$5.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.

The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.

MiniMed Group Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
53% Buy47% Sell
Avg holding period · 7 Days
MMED
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About MiniMed Group Inc. Common Stock

MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.

Read more on MMED →